Drugs / deulorlatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05441956 | Apr 2021 → Aug 2025 overdue | non-small cell lung carcinoma | Shenzhen TargetRx Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | deulorlatinib | “Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial.” PMID 39551469 ↗ Nov 2024 |
| Known as | TGRX-326 | “Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial.” PMID 39551469 ↗ Nov 2024 |
| Action | Inhibit | “Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor.” PMID 39551469 ↗ Nov 2024 |
| Target | ALK | “Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor.” PMID 39551469 ↗ Nov 2024 |
| Target | ROS1 | “Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor.” PMID 39551469 ↗ Nov 2024 |